A Retrospective Study Evaluating Efficacy and Safety Of Erythropoietic-Stimulating Agents (ESA) With Ruxolitinib In Patients With Myelofibrosis.

Trial Profile

A Retrospective Study Evaluating Efficacy and Safety Of Erythropoietic-Stimulating Agents (ESA) With Ruxolitinib In Patients With Myelofibrosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Darbepoetin alfa (Primary) ; Epoetin alfa (Primary) ; Epoetin beta (Primary) ; Epoetin theta (Primary) ; Epoetin zeta (Primary) ; Ruxolitinib (Primary)
  • Indications Anaemia; Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 New trial record
    • 06 Dec 2016 Results (analysis date July 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top